JP2005512574A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512574A5
JP2005512574A5 JP2003554914A JP2003554914A JP2005512574A5 JP 2005512574 A5 JP2005512574 A5 JP 2005512574A5 JP 2003554914 A JP2003554914 A JP 2003554914A JP 2003554914 A JP2003554914 A JP 2003554914A JP 2005512574 A5 JP2005512574 A5 JP 2005512574A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
acid sequence
amino acid
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003554914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512574A (ja
Filing date
Publication date
Priority claimed from US10/027,736 external-priority patent/US6911321B2/en
Application filed filed Critical
Publication of JP2005512574A publication Critical patent/JP2005512574A/ja
Publication of JP2005512574A5 publication Critical patent/JP2005512574A5/ja
Withdrawn legal-status Critical Current

Links

JP2003554914A 2001-12-19 2002-12-03 非ヒト霊長類Fcレセプターおよびその利用方法 Withdrawn JP2005512574A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/027,736 US6911321B2 (en) 2001-12-19 2001-12-19 Non-human primate Fc receptors and methods of use
PCT/US2002/038805 WO2003054213A2 (en) 2001-12-19 2002-12-03 NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE

Publications (2)

Publication Number Publication Date
JP2005512574A JP2005512574A (ja) 2005-05-12
JP2005512574A5 true JP2005512574A5 (https=) 2006-07-13

Family

ID=21839483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554914A Withdrawn JP2005512574A (ja) 2001-12-19 2002-12-03 非ヒト霊長類Fcレセプターおよびその利用方法

Country Status (7)

Country Link
US (3) US6911321B2 (https=)
EP (1) EP1456222A4 (https=)
JP (1) JP2005512574A (https=)
AU (1) AU2002357071A1 (https=)
CA (1) CA2466885A1 (https=)
IL (1) IL161543A0 (https=)
WO (1) WO2003054213A2 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
JP3993783B2 (ja) * 2002-04-04 2007-10-17 株式会社小糸製作所 車両用灯具の設計方法、設計システム、プログラム、及び記録媒体
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
CA2512974A1 (en) * 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
NZ547629A (en) * 2003-11-26 2009-08-28 Max Planck Gesellschaft Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP1858925A2 (en) * 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Fc受容体およびその製造方法
EP3048112B1 (en) * 2013-09-18 2020-03-11 Tosoh Corporation Fc-BINDING PROTEIN, METHOD FOR PRODUCING SAID PROTEIN, AND ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHODS FOR PURIFYING AND IDENTIFYING ANTIBODY USING SAID ADSORBENT
CN111690052B (zh) * 2014-04-08 2024-06-04 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3702462B1 (en) 2017-10-27 2024-10-09 Tosoh Corporation Fc-BINDING PROTEIN EXHIBITING IMPROVED ALKALINE RESISTANCE, METHOD FOR PRODUCING SAID PROTEIN, ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHOD FOR SEPARATING ANTIBODY USING SAID ANTIBODY ADSORBENT
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4287828A4 (en) * 2021-02-02 2025-01-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
WO2024232948A1 (en) * 2023-05-05 2024-11-14 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
WO1994025570A1 (en) * 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies

Similar Documents

Publication Publication Date Title
JP2005512574A5 (https=)
JP4309910B2 (ja) 発現ツールとしてのfkbpシャペロンの使用
EP1730198B1 (en) Adzymes and uses thereof
TWI598361B (zh) Cx3cr1-結合多肽
Harari et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
AU2018390418A1 (en) Engineered IL-2 FC fusion proteins
KR20100084996A (ko) 면역글로불린 단편을 이용한 생리활성 단백질 또는 펩타이드의 생산 방법
US20250195673A1 (en) Compositions and methods for selective depletion of target molecules
KR20170065026A (ko) 대사 장애 치료용으로 이용되는 조성물 및 방법
WO2020099871A1 (en) Single domain antibodies that bind human serum albumin
CN113227134A (zh) 抗体的Fc区变体
CN105518023A (zh) Fab区域结合性肽
CA2636075A1 (en) Chimaeric fusion protein with superior chaperone and folding activities
CN113840835A (zh) 结合分子
CA3206901A1 (en) Paraoxonase fusion polypeptides and related compositions and methods
CN115175920A (zh) 加条形码的xten多肽及其组合物以及其制备和使用方法
JP2005518212A5 (https=)
JP2021525807A (ja) ポリユビキチンリンカーに結合された線形多機能性マルチマー生体分子及びその用途
WO1995006737A1 (en) Glycophorin binding protein (gbp130) fusion compositions
CN100427506C (zh) 从融合多肽制备感兴趣的多肽的方法
CN102977205A (zh) 骨保护素变异蛋白
CA3237004A1 (en) B cell activating factor (baff)-a proliferation inducing ligand (april) dual inhibitors
JP2009536821A5 (https=)
WO2005058956A1 (en) Cytokine binding domains
US20220259290A1 (en) Innovative production technique for antibody-enzyme